Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $39 to $34.
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $39 to $34.